丸美生物: 广东丸美生物技术股份有限公司关于2025年半年度募集资金存放与使用情况的专项报告

Summary of Key Points Core Viewpoint The report provides an overview of the fundraising activities and the management of raised funds by Guangdong Marubi Biotechnology Co., Ltd. for the first half of 2025, highlighting the total amount raised, its usage, and the management practices in place to ensure compliance with regulations. Group 1: Fundraising Overview - The company raised a total of RMB 842,140,000.00 from the issuance of 41 million shares at RMB 20.54 per share, with net proceeds amounting to RMB 790,001,978.42 after deducting issuance costs of RMB 52,138,021.58 [1] - As of June 30, 2025, the total amount used from the raised funds was RMB 535,181,303.64, with a remaining balance of RMB 270,426,824.67 in the dedicated fundraising account [1][2] Group 2: Fund Management Practices - The company has established a dedicated fund management system in compliance with relevant regulations, including the opening of special accounts for fundraising and signing of tripartite supervision agreements with sponsors and banks [1] - The remaining balance in the fundraising account as of June 30, 2025, is distributed across various banks, with RMB 236,579,195.01 held in one account and RMB 25,918,241.87 in another [1] Group 3: Fund Usage and Projects - The company has not used idle funds for temporary working capital or to repay bank loans, nor has it changed the use of raised funds for ongoing or new projects [2][3] - The construction of the "Cosmetics Intelligent Manufacturing Factory" has been completed, but production line construction is still pending, with plans for future capacity and project arrangements based on market conditions [2][3] Group 4: Compliance and Reporting - The company has adhered to the fundraising management regulations and has not encountered any significant violations in the use of raised funds [2] - There are no changes in the implementation location or method of the fundraising projects, and no early investments or replacements have occurred [3]